Exelixis Presents Results Of Cabozantinib On Metastatic Castration-Resistant Prostate Cancer
18/9 16:31
(RTTNews) - Exelixis Inc. (EXEL) said that it presented detailed results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib or CABOMETYX in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer or CRPC at the 2021...